Palbociclib: A New Option for Front-Line Treatment of Metastatic, Hormone Receptor–Positive, HER2-Negative Breast Cancer

類似資料

• Hormone receptor–positive, HER2-negative metastatic breast cancer: redrawing the lines
  著者:: Matutino, A., 等
  出版事項: (2018)
• Palbociclib for the Treatment of Estrogen Receptor–Positive, HER2-Negative Metastatic Breast Cancer
  著者:: Morikawa, Aki, 等
  出版事項: (2015)
• Palbociclib in the first line combination hormone therapy of HER2- negative metastatic hormone-dependent breast cancer. Clinical follow-up
  著者:: M. A. Frolova, 等
  出版事項: (2018-07-01)
• Chemotherapy Options beyond the First Line in HER-Negative Metastatic Breast Cancer
  著者:: Lorusso, Vito, 等
  出版事項: (2020)
• Palbociclib added to ongoing endocrine therapy for hormone receptor-positive HER2-negative metastatic breast cancer: A case report series
  著者:: Schettini, Francesco, 等
  出版事項: (2020)